title: [Response to S-1+paclitaxel in far-advanced gastric cancer].
abstract: The patient was a 55-year-old man who was treated with S-1 and paclitaxel(PTX)combination chemotherapy for inoperable advanced gastric cancer in whom an abdominal CT examination had revealed peritoneal dissemination, pancreatic invasion, and ascites. A total of 15 courses of S-1 120 mg/day for 2 weeks followed by a 2-week rest period and PTX 90 mg/ body on day 1, 8, and 15 were administered. The CT examination after the completion of chemotherapy showed resolution of the ascites, and no evidence of peritoneal dissemination was observed on the images. The tumor marker values had also decreased, but because of severe manifestations of pyloric stenosis, distal gastrectomy and D1 lymph node dissection were performed. Intraoperative exploration revealed total scarring of the peritoneal dissemination and no evidence of pancreatic invasion. We reported this case because of the long-term combination chemotherapy with no major adverse effects and the fact that resection was possible.
authors.affiliation: Dept. of Surgery, Sagamihara Kyoudo Hospital.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Aizaki
authors.forename: Satoru
authors.initials: S
authors.lastname: Kohno
authors.forename: Kazunori
authors.initials: K
authors.lastname: Sasaki
authors.forename: Daisuke
authors.initials: D
authors.lastname: Fujihira
authors.forename: Takuya
authors.initials: T
authors.lastname: Koike
authors.forename: Tohgo
authors.initials: T
authors.lastname: Norimatsu
authors.forename: Kentaro
authors.initials: K
authors.lastname: Funatsu
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ohya
authors.forename: Miwa
authors.initials: M
authors.lastname: Shino
authors.forename: Toru
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Tsunehisa
authors.initials: T
authors.lastname: Matsushita
authors.forename: Takao
authors.initials: T
authors.lastname: Hokari
authors.forename: Shinjiro
authors.initials: S
authors.lastname: Kawakami
authors.forename: Seigo
authors.initials: S
authors.lastname: Takano
authors.forename: Akio
authors.initials: A
authors.lastname: Kazama
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel